PhD KINGS COLLEGE LONDON London, England, United Kingdom
Introduction: Oral delivery of siRNA remains challenging due to poor epithelial compatibility, limited gastrointestinal stability, and barrier disruption associated with conventional lipid nanoparticles. Milk-derived extracellular vesicles (mEVs) offer superior biocompatibility and intestinal stability but suffer from low RNA loading efficiency. This study aims to develop mEV–LNP hybrid nanoparticles that combine efficient siRNA delivery with preservation of intestinal epithelial barrier function for applications in intestinal inflammation.
Learning Objectives:
participant will be able to describe barrier-compatible oral siRNA delivery with milk EV–LNP hybrids.
participant will be able to describe barrier-compatible oral siRNA delivery with milk EV–LNP hybrids.
participant will be able to assess hybrid nanoparticle performance for anti-inflammatory siRNA delivery.
